Generation of MERS-CoV Pseudotyped Viral Particles for the Evaluation of Neutralizing Antibodies in Mammalian Sera
Pseudotyped viral particle production has been used extensively and broadly for many viruses to evaluate levels of neutralizing antibodies, viral entry inhibitors and vaccine immunogenicity. This assay is extremely safe and useful alternative to live virus-based assay without the need for high containment facilities. In this chapter, we describe the generation of MERS-CoV pseudotyped viral particles (MERSpp) expressing full-length spike protein using second-generation lentiviral packaging system. This platform is optimized to generate high titer of MERSpp and to test sera from different mammalian species.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2099 |
|---|---|
| Enthalten in: |
Methods in molecular biology (Clifton, N.J.) - 2099(2020) vom: 27., Seite 117-126 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Almasaud, Abdulrahman [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.09.2020 Date Revised 21.09.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1007/978-1-0716-0211-9_10 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM304830992 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM304830992 | ||
| 003 | DE-627 | ||
| 005 | 20231225115830.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/978-1-0716-0211-9_10 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1016.xml |
| 035 | |a (DE-627)NLM304830992 | ||
| 035 | |a (NLM)31883092 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Almasaud, Abdulrahman |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Generation of MERS-CoV Pseudotyped Viral Particles for the Evaluation of Neutralizing Antibodies in Mammalian Sera |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.09.2020 | ||
| 500 | |a Date Revised 21.09.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Pseudotyped viral particle production has been used extensively and broadly for many viruses to evaluate levels of neutralizing antibodies, viral entry inhibitors and vaccine immunogenicity. This assay is extremely safe and useful alternative to live virus-based assay without the need for high containment facilities. In this chapter, we describe the generation of MERS-CoV pseudotyped viral particles (MERSpp) expressing full-length spike protein using second-generation lentiviral packaging system. This platform is optimized to generate high titer of MERSpp and to test sera from different mammalian species | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a MERS-CoV | |
| 650 | 4 | |a Neutralization assay | |
| 650 | 4 | |a Pseudotype viral particles | |
| 650 | 4 | |a Pseudovirus | |
| 650 | 4 | |a Transfection | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a Viral Vaccines |2 NLM | |
| 700 | 1 | |a Alharbi, Naif Khalaf |e verfasserin |4 aut | |
| 700 | 1 | |a Hashem, Anwar M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Methods in molecular biology (Clifton, N.J.) |d 1984 |g 2099(2020) vom: 27., Seite 117-126 |w (DE-627)NLM074849794 |x 1940-6029 |7 nnns |
| 773 | 1 | 8 | |g volume:2099 |g year:2020 |g day:27 |g pages:117-126 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/978-1-0716-0211-9_10 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2099 |j 2020 |b 27 |h 117-126 | ||